ClinicalTrials.gg

Program

LT3001

A development code. Also written as “LT3001 Drug Product”, “LT3001 Drug:high dose” and “LT3001 Drug: low dose”.

Its studies are mostly in Ischemic Stroke, led by 2 companies.

Furthest: phase 2, since Sep 5, 20197 company-led studies, 4 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lumosa Therapeutics52 open or runningphase 2since Sep 5, 2019Sep 5, 2019Dec 31, 2026phase 2 · NCT05198323
Shanghai Pharmaceuticals22 open or runningphase 2since Jan 9, 2023Jan 9, 2023Dec 10, 2026phase 2 · NCT05686642

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2019First study: phase 2 study in Ischemic StrokeNew to Lumosa TherapeuticsLumosa Therapeutics · NCT04091945 · 24 enrolled · United States, Taiwan
  2. Mar 5, 2021Phase 1 study in Ischemic StrokeLumosa Therapeutics · NCT04809818 · 65 enrolled · United States
  3. Jan 3, 2022Phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT05198323 · 66 enrolled · United States, Taiwan
  4. May 31, 2022Phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT05403866 · 89 enrolled · United States
  5. Jan 9, 2023Shanghai Pharmaceuticals's first study: phase 2 study in Ischemic StrokeNew to Shanghai PharmaceuticalsShanghai Pharmaceuticals · NCT05686642 · 300 planned · China
  6. Aug 5, 2026Phase 2 study in Ischemic StrokeShanghai Pharmaceuticals · NCT07754825 · 300 planned · China
  7. Oct 16, 2026Phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT07890298 · 10 planned · Taiwan

Ahead

  1. Dec 10, 2026Primary completion: phase 2 study in Ischemic StrokeShanghai Pharmaceuticals · NCT05686642
  2. Dec 31, 2026Primary completion: phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT05198323
  3. Dec 31, 2027Primary completion: phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT07890298
  4. Dec 31, 2027Primary completion: phase 2 study in Ischemic StrokeShanghai Pharmaceuticals · NCT07754825

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07890298Ischemic Stroke · Taiwan2RecruitingLumosa TherapeuticsDec 31, 202710
NCT07754825Ischemic Stroke · China2Not yet recruitingShanghai PharmaceuticalsDec 31, 2027300
NCT05686642Ischemic Stroke · China2RecruitingShanghai PharmaceuticalsDec 10, 2026300
NCT05403866Ischemic Stroke · United States2CompletedLumosa TherapeuticsMay 23, 202589
NCT05198323Ischemic Stroke · United States, Taiwan2Active, not recruitingLumosa TherapeuticsDec 31, 202666
NCT04809818Ischemic Stroke · United States1CompletedLumosa TherapeuticsAug 5, 202165
NCT04091945Ischemic Stroke · United States, Taiwan2CompletedLumosa TherapeuticsFeb 22, 202124

How it is read

Names in the registry

  • “LT3001 Drug Product”, 4 entries
  • “LT3001 Drug:high dose”, 2 entries
  • “LT3001 Drug: low dose”, 1 entry
  • “LT3001 Drug:low dose”, 1 entry
  • “LT3001 drug product”, 1 entry

Codes read as this program: LT3001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.